Coronavirus (Covid -19) and Type 2 Diabetes
New safety guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) suggests SGLT2 inhibitor treatment which includes Invokana, should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses and ketone levels measured, preferably in blood rather than urine. Treatment may be restarted when the ketone values are normal and the patient’s condition has stabilised.
It is important that people with diabetes follow the sick day rules should they become ill from any illness.
Protect the kidneys
Protect the heart
Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise. For treatment of diabetic kidney disease (DKD) in adults with T2DM as add-on to standard of care, a dose of 100 mg once-daily should be used. See SmPC section 4.2 for dosing details.
Protect the kidneys
Protect the heart
Invokana is indicated for the treatment of adults with insufficiently
controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise.
For treatment of diabetic kidney disease (DKD) in adults with T2DM as
add-on to standard of care, a dose of 100 mg once-daily should be used.
See
SmPC section 4.2 for dosing details.
References
- Reference 21
- Reference 22
- Reference 23
- Reference 24
Date of preparation: October 2020 | Job code:UK-INV-2000072
